Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program

SAN DIEGO–(BUSINESS WIRE)—- $GOSS–Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) from its ongoing Phase 1/2 study of GB1275 in patients with selected solid tumors. The KEYNOTE